Nilotinib Stada (Nilotinib)

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in chronic myeloid leukemia.

• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and achieves hematologic remission.
• Chronic myeloid leukemia (accelerated phase): provides cytogenetic response and disease control after prior therapy failure.
• Chronic myeloid leukemia (post‑imatinib resistance): offers an alternative targeted option for patients who have not responded to first‑line treatment.

• Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL fusion protein, inhibiting its tyrosine kinase activity. By blocking downstream signaling cascades such as the RAS‑RAF‑MEK‑ERK and PI3K‑AKT pathways, it prevents proliferation and induces apoptosis of malignant leukemic cells. The drug also inhibits the related kinases KIT and PDGFR, contributing to its antineoplastic effect. This targeted inhibition results in disease stabilization in responsive patients.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often transient.
• Headache: mild cranial discomfort.
• Rash: skin redness or itching.
• Fatigue: generalized tiredness.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusive disease and heart failure.
• QT interval prolongation: may lead to serious arrhythmias.
• Pancreatitis: inflammation of the pancreas with abdominal pain.
• Severe hepatic injury: marked elevation of liver enzymes or hepatitis.
• Neutropenia: dangerously low white blood cell count.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Nilotinib therapy, several precautionary measures should be considered to ensure patient safety.

• Cardiac monitoring: assess baseline ECG and watch for ischemic symptoms.
• Blood count surveillance: perform regular CBC to detect neutropenia or anemia.
• Liver function testing: monitor ALT, AST and bilirubin levels periodically.
• Avoid strong CYP3A4 inhibitors: concomitant use can increase drug exposure.
• Dose adjustment in hepatic impairment: reduce dose in patients with moderate liver dysfunction.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Nilotinib interacts with several medicines; understanding the level of interaction helps manage therapy safely.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly raise nilotinib plasma levels.
• QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of serious cardiac arrhythmias.
• Antacids raising gastric pH (e.g., aluminum‑magnesium hydroxide): reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib effectiveness.
• Warfarin: may require INR monitoring due to altered anticoagulant effect.
• Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for increased statin toxicity.
• Proton pump inhibitors: may modestly affect drug exposure, consider timing of administration.